Talk:Amlodipine/atorvastatin

"Controversy" section
I've removed the "Controversy" section which suggests that combination drugs are "money grabs". This information is more a criticism of Fixed dose combination in general (and I note that similar information is already a part of that article). Additionally, the section was completely unreferenced and made several dubious claims. If you want to re-add the information, please provide proof and explain specifically how it relates to Caduet. &mdash;/M endaliv /2¢/Δ's/ 21:36, 31 July 2008 (UTC)


 * Caduet is a combination of two medications, amlodipine, whose patent has recently expired, and atorvastatin, whose patent expires in March of 2010. By combining the two into a single dosage unit, Pfizer is able to receive a new patent valid until August 2018, and thus charge a premium for drugs which would otherwise be cheaply available. If this is not an obvious abuse of the FDA regulations, I don't know what is. With this kind of behavior, it could become accepted practice to patent any effective drug combination in order to simply generate more profit. Hydrocodone and carisoprodol are both effective for back pain relief, Hey, let's toss them both in a pill and call it Spinogesic! Then we could charge twice as much as the price of both combined! —Preceding unsigned comment added by 70.217.128.225 (talk) 03:24, 1 August 2008 (UTC)
 * Wikipedia is not a soapbox. Unless you can provide some proof in reliable sources of a controversy surrounding Caduet, that section shouldn't be re-added. &mdash;/M endaliv /2¢/Δ's/ 03:30, 1 August 2008 (UTC)


 * Here[] is a Wall Street Journal article outlining Pfizer's plan to switch Norvasc users to Caduet in order to increase profits. Here[ is a Washington Post article also relating to the marketing ploy. I'm not making this stuff up. —Preceding [[Wikipedia:Signatures|unsigned]] comment added by 70.217.3.165 (talk) 15:34, 1 August 2008 (UTC)